Clinical Research Directory

Inclusion Criteria: 1. Untreated newly diagnosed T2DM patients; 2. Age ≥ 18 years old; 3. 8.0% ≤ HbA1c\<11.0%; 4. 19 kg/m2 ≤ BMI\<35 kg/m2; 5. eGFR ≥ 60 ml/min1.73m2; 6. Voluntarily participate and sign an informed consent form Exclusion Criteria: 1. Pregnant and lactating women, as well as women of childbearing age who are unwilling to take reliable contraceptive measures; 2. Individuals who are known to be allergic to Henggliflozin, Regagliptin, or Metformin; 3. Other types of diabetes except type 2 diabetes; 4. Type 2 diabetes with a history of ketoacidosis (DKA) in the last 6 months; 5. NYHA cardiac grade IV patients; 6. Within 30 days prior to the screening visit, admission due to acute coronary syndrome (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, or unstable angina), percutaneous coronary intervention, or cardiac surgery; Or plan to undergo percutaneous coronary intervention or cardiac surgery within 3 months. 7. Confirmed respiratory system diseases (such as chronic obstructive pulmonary disease, pulmonary arterial hypertension, etc.); 8. History of acute or chronic pancreatitis; 9. Uncontrolled hypertension, defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg (average of three supine blood pressure measurements) during screening visits; 10. Patients with orthostatic hypotension and/or systolic blood pressure\<90 mmHg at visit 0 or visit 1, or clinically diagnosed as having low blood volume; 11. Diagnosed malignant tumor patients with an expected life expectancy of less than 1 year; 12. Patients with a history of recurrent urinary and reproductive tract infections (judged by clinical doctors); 13. Patients who participate in other clinical trials within 3 months; 14. Alcohol or drug addiction. 15. In addition to the above, the researchers determined that patients who are not suitable to participate in this clinical trial.